Mbx Biosciences, INC Schedule 13D activist filings

Frazier Life Sciences entities and individuals have filed an amendment to Schedule 13D, reporting changes in beneficial ownership of MBX Biosciences, Inc. common stock.

OrbiMed Advisors and its affiliates have reduced their beneficial ownership in MBX Biosciences, Inc. to 7.7% due to share sales and an increase in outstanding shares.

New Enterprise Associates 17 and its affiliates have reported a decrease in their beneficial ownership of MBX Biosciences, Inc. common stock to 8.1% due to an increase in outstanding shares.

OrbiMed Advisors and its affiliates reported a decrease in their beneficial ownership of MBX Biosciences, Inc. common stock to 9.0% due to an increase in the issuer's outstanding shares.

Norwest Venture Partners and its affiliates reported a decrease in their beneficial ownership of MBX Biosciences common stock to 4.8% following the company's recent public offering.

Frazier Life Sciences and affiliated entities have increased their beneficial ownership in MBX Biosciences, Inc., with a recent purchase of 666,666 shares at $18.00 per share.

Frazier Life Sciences funds filed an amended Schedule 13D to clarify beneficial ownership of MBX Biosciences, Inc. common stock, correcting prior attributions.